Evaluation of 2-year outcomes following intravitreal bevacizumab (IVB) for aggressive posterior retinopathy of prematurity

ABSTRACTPurpose:To evaluate 2-year outcomes following intravitreal bevacizumab (IVB) as monotherapy for aggressive posterior retinopathy of prematurity (APROP).Methods:Medical records of 40 infants were retrospectively reviewed. Group I included infants who had received IVB injections for APROP. Group II included infants who underwent laser treatment for APROP. Anatomic and refractive outcomes and the presence of anisometropia and strabismus were assessed at follow-up examinations.Results:Group I included 48 eyes of 25 infants (11 males) with a mean gestational age (GA) of 26.40 ± 1.82 weeks and a mean birth weight (BW) of 901.40 ± 304.60 g. Group II included 30 eyes of 15 infants (6 males) with a mean GA of 27.30 ± 1.82 weeks and a mean BW of 941.00 ± 282.48 g. GA, BW, and gender distributions were similar between groups (P=0.187, P=0.685, and P=1.000, respectively). Refractive errors were significantly less myopic in group I (0.42 ± 3.42 D) than in group II (-6.66 ± 4.96 D) at 2 years (P=0.001). Significantly higher rates of anisometropia and strabismus were observed in group II than in group I (P=0.009 and P=0.036, respectively).Conclusions:The study demonstrated that IVB monotherapy can be useful in the treatment of APROP. The decreased incidence of early unfavorable refractive and functional outcomes in the IVB group compared with the laser group showed a potential benefit for patients treated with IVB, and this needs to be better evaluated in future prospective studies.

摘要
目的：评估玻璃体腔注射贝伐单抗（intravitreal bevacizumab, IVB）单药治疗侵袭性后部早产儿视网膜病变（aggressive posterior retinopathy of prematurity, APROP）后的2年随访结局。
方法：本研究回顾性分析了40例婴儿的临床病历资料。将研究对象分为两组：第I组为接受IVB单药治疗的APROP患儿，第II组为接受激光光凝治疗的APROP患儿。在随访检查中，对两组患儿的解剖学结局、屈光状态，以及屈光参差和斜视的发生情况进行评估。
结果：第I组共纳入25例婴儿（男11例）的48只患眼，其平均胎龄（gestational age, GA）为26.40±1.82周，平均出生体重（birth weight, BW）为901.40±304.60g。第II组共纳入15例婴儿（男6例）的30只患眼，其平均胎龄为27.30±1.82周，平均出生体重为941.00±282.48g。两组间胎龄、出生体重及性别分布均无显著统计学差异（分别对应P=0.187、P=0.685、P=1.000）。随访至2年时，第I组患儿的屈光不正度数显著低于第II组（0.42±3.42 D 与 -6.66±4.96 D，P=0.001）。第II组患儿的屈光参差及斜视发生率显著高于第I组（分别对应P=0.009、P=0.036）。
结论：本研究证实，IVB单药治疗可应用于APROP的临床治疗。相较于激光治疗组，IVB治疗组早期不良屈光及功能结局的发生率更低，提示IVB治疗或可为APROP患儿带来潜在获益，该结论仍需未来的前瞻性研究进一步验证。